Trial Profile
PhaseI study with multiple, ascending doses of NA808 in patients with chronic hepatitis C viral infection.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 27 May 2016
Price :
$35
*
At a glance
- Drugs NA 808 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 27 May 2016 New trial record